Herbal Therapy for the Treatment of Acetaminophen-Associated Liver Injury: Recent Advances and Future Perspectives

Ling Chang†, Dongwei Xu‡, Jianjun Zhu‡, Guangbo Ge*, Xiaoni Kong* and Ying Zhou†

† Department of Gastroenterology, The Seventh People’s Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China; ‡ Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; * Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China; † Central Laboratory, Department of Liver Diseases, Institute of Clinical Immunology, ShuGuang Hospital Affiliated to Shanghai University of Chinese Traditional Medicine, Shanghai, China

Acetaminophen (APAP) overdose is the leading cause of drug-induced liver injury worldwide, and mitochondrial oxidative stress is considered the major event responsible for APAP-associated liver injury (ALI). Despite the identification of N-acetyl cysteine, a reactive oxygen species scavenger that is regarded as an effective clinical treatment, therapeutic effectiveness remains limited due to rapid disease progression and diagnosis at a late phase, which leads to the need to explore various therapeutic approaches. Since the early 1990s, a number of natural products and herbs have been found to have hepatoprotective effects against APAP-induced hepatotoxicity in terms of acute liver failure prevention and therapeutic amelioration of ALI. In this review, we summarize the hepatoprotective effects and mechanisms of medicinal plants, including herbs and fruit extracts, along with future perspectives that may provide guidance to improve the current status of herbal therapy against ALI.

Keywords: herbal therapy, acetaminophen, liver injury, P450 enzyme, oxidative stress, gut microbiota

INTRODUCTION

Acetaminophen (APAP) is a commonly used analgesic and antipyretic drug that is found in a number of combined prescriptions, including Tylenol with codeine and Hycotab (Aminoshariae and Khan, 2015). Although its effectiveness and safety were confirmed at recommended doses, the APAP overdose causes hepatotoxicity that leads to acute liver failure (ALF) (Bunchorntavakul and Reddy, 2018). According to the ALF Study Group in the United States, APAP-associated toxicity contributes to approximately 46% of all cases of ALF in adults, which far exceeds idiosyncratic drug-induced liver injury (DILI) by more than fourfolds (Ostapowicz et al., 2002; Lee, 2013).

Accumulating evidence has highlighted that APAP-induced oxidative stress and mitochondrial dysfunction are the fundamental factors in the pathogenesis of APAP-associated liver injury (ALI); thus, N-acetyl cysteine (NAC), a scavenger of reactive oxygen species (ROS), is considered a standard therapeutic option for APAP overdose (Jaeschke et al., 2012). However, due to the narrow
therapeutic window, severe adverse effects, and rapid disease progression, the therapeutic efficacy of NAC is still limited (Du et al., 2016). For patients at the advanced stage, liver transplantation is the only way to improve survival outcomes (Craig et al., 2010). Therefore, new treatments that are superior to NAC in terms of therapeutic efficacy and safety are required in clinical practice.

Recently, herbal medicine was found to be a promising therapeutic approach for ALI. Several herbal components were reported to have the same therapeutic effect as NAC (Chen et al., 2009; Mukazayire et al., 2010; Tien et al., 2014). In a previous study, the effectiveness of the treatment was significantly noticed when it was administered after APAP, but not as a pretreatment. These underlying limitations regarding the applicability and effectiveness of herbal therapy have been modified and improved in recent years by direct application in an APAP overdose setting. In this review, we highlighted recent advances and new findings regarding the impact, effectiveness, and underlying mechanisms of herbal therapies in ALI.

Underlying Mechanisms of APAP and ALI

The majority of APAP is conjugated with glucuronic acid and then excreted through the kidney when consumed at therapeutic doses. The remnants of the dose form reactive metabolites (N-acetyl-p-benzoquinone imine; NAPQI) by cytochrome P450 enzymes (McGill and Jaeschke, 2013). Although the reactivity of NAPQI is high, it is barely harmful at the therapeutic dose because of its abundant glutathione storage and excretion through bile. In contrast, an overdose of APAP causes hepatotoxicity by saturating the sulfation pathway and generating NAPQI that leads to a robust reaction between NAPQI and hepatic glutathione stores, which subsequently depletes glutathione (Xie et al., 2015).

Currently, APAP protein adduct formation and release into the circulation is being utilized as a biomarker for APAP overdose (Davern et al., 2006). However, these molecules are also identified in the majority of subjects taking a therapeutic dose of APAP, and protein-derived APAP-cysteine is detectable after supertherapeutic consumption of APAP without hepatotoxicity (O’Malley et al., 2015). Recently, Roberts et al. (2017) differentiated ALI from the others using APAP protein adducts by developing an immunoassay that rapidly measures APAP protein adducts to identify ALF. Therefore, considering the presence of APAP protein adducts at the therapeutic dose of APAP, formation of protein adducts on mitochondrial proteins rather than the overall formation of protein adducts may be the reason for cellular toxicity, which has been considered a key factor for necrotic cell death in previous years (Jollow et al., 1973; Hu et al., 2016).

Deppleted glutathione by NAPQI leads to increased H2O2 release that oxidizes thioredoxin and induces the disassociation of thioredoxin from apoptosis-signaling-regulating kinase 1 (ASK-1), triggering self-activation of ASK-1, which phosphorylates mitogen-activated protein kinase 4/7 and activates c-Jun N-terminal kinase (JNK) (Hanawa et al., 2008; Nakagawa et al., 2008). Activated JNK contributes to the dysfunction of the electron transport chain and increased ROS. In addition, sustained JNK activation was amplified mitochondrial ROS and forms a self-sustaining activation loop (Win et al., 2016). Furthermore, p-JNK leads to the activation of Bax and translocation to mitochondria to trigger the mitochondrial permeability transition (MPT) pore formation, along with collapsed ATP depletion and membrane potential, eventually causing DNA fragmentation and necrosis (Bajt et al., 2006; Kim et al., 2006). In recent years, Kim et al. (2015) demonstrated that metformin, a first-line drug for treatment of type 2 diabetes mellitus, has therapeutic effects against ALI by inhibiting p-JNK via upregulation of Gadd45β. However, a follow-up study showed that protective effect of metformin treatment in APAP-associated hepatotoxicity was independent of JNK (Du et al., 2016). This effect may be associated with other factors, such as the inhibition of ROS production. Therefore, further confirmation of the underlying mechanisms of metformin against APAP-associated hepatotoxicity is necessary. Apart from metformin, p53 (a tumour suppressor protein) is activated due to oxidative stress in ALI, and protective during liver injury via inhibition of JNK, but also delays liver regeneration (Huo et al., 2017; Borude et al., 2018). Therefore, p53 seems not an ideal target for ALI considering its double-sided role in ALI pathogenesis.

Moreover, many other signalling pathways are promoted in response to the oxidative stress in APAP overdose. Nuclear factor erythroid 2-related factor 2 (Nrf2) is notably representative and is activated by NAPQI-induced redox status changes. Nrf2 was found to participate in transcriptional activation of antioxidant enzymes that act as a cell defensive system to detoxify NAPQI (Goldring et al., 2004). In addition to activation by NAPQI, the Nrf2 signalling pathway is also regulated by protein tyrosine phosphatase 1B (PTP1B) and M1 muscarinic receptors (M1Rs) (Mobasher et al., 2013; Urrunaga et al., 2015). APAP-associated hepatotoxicity is ameliorated by promoting the Nrf2 system in mice without PTP1B or M1R, indicating that PTP1B and/or M1R may be promising therapeutic targets in ALI. Considering the positive impact of Nrf2 in ameliorating oxidative stress, a number of bioactive components that exert protective effect against APAP-associated hepatotoxicity have been identified and reported, including caffeic acid that activates the Keap1-Nrf2 antioxidant defense system (Pang et al., 2016), carnosic acid that promotes nuclear translocation of Nrf2 (Guo et al., 2016), and esculetinoid A that activates Nrf2 via AMP-activated kinase/Akt/glycogen synthase kinase 3 pathway (Wang et al., 2016). These studies reveal that pretreatment with the Nrf2-activating natural products prevents against ALI in APAP overdose. Overall, glutathione depletion, oxidative stress, and mitochondrial damage are the critical underlying mechanisms of ALI (Figure 1).

Cytochrome P450-Mediated Metabolic Activation

APAP metabolic activation is mainly catalyzed by the cytochrome P450 enzyme and the reactive metabolite associated with hepatotoxicity is commonly considered to be NAPQI (Dahlin et al., 1984). APAP overdose results in excess NAPQI formation that depletes glutathione levels and binds to proteins. A previous study confirmed increased turnover of...
glutathione after increasing APAP dose (Jollow et al., 1973). Moreover, APAP-protein adducts can be measured in patients with APAP overdose (Davern et al., 2006). In addition, cysteine residues are the main targets for covalent alteration by the reactive intermediate of APAP (Streeter et al., 1984).

Both alcohol and isoniazid induce CYP2E1 and affect APAP-induced ALI by increasing NAPQI, the hepatotoxic metabolite of APAP, indicating that CYP2E1 may be the major P450 contributing to conversion of APAP to NAPQI (Zand et al., 1993; Thummel et al., 2000). Accordingly, less susceptibility of alcohol and isoniazid was observed in CYP2E1-knockout mice in an ALI setting (Lee et al., 1996). Apart from CYP2E1, CYP1A2, 2D6, and 3A4 have also been found to activate APAP in various models (Patten et al., 1993; Thummel et al., 1993; Dong et al., 2000). Beta-catenin-deficient mice have been reported to show elimination of Cyp2e1 and 1a2 proteins, which are associated with resistance against APAP hepatotoxicity (Sekine et al., 2006). Moreover, Cyp2e1/- mice showed resistance to the APAP high dose-associated hepatotoxicity, whereas human CYP2E1 transgenic mice were susceptible, suggesting that CYP2E1 is the major P450 enzyme participating in APAP activation (Cheung et al., 2005). Furthermore, APAP-protein adducts were detected after APAP treatment in human HepaRG cells that express low CYP2E1 levels (Antherieu et al., 2010). Therefore, CYP2E1 is the primary enzyme contributing to the conversion of APAP to its reactive intermediate along with other P450s, such as CYP1A2 and CYP3A4. At normal therapeutic dose, APAP is mainly metabolized via O-glucuronidation (50%–70%) and O-sulfation (approximately 25%) pathways and forms the corresponding conjugates that can be easily excreted by the kidney. Moreover, a minor proportion of this agent can be metabolized within the liver by the cytochrome P450 enzymes (primarily by CYP2E1) to NAPQI, which is detoxified by conjugation and excreted in the glutathione or NAC forms (Figure 2). However, when the drug is taken in an overdose, the Uridine diphosphate-glucuronosyltransferases (UGTs) and sulfotransferases (SULTs) in the human liver that participate in APAP detoxification become saturated, and a considerable proportion of this drug is activated by human CYPs (primarily CYP2E1).

For the treatment of AALI (APAP-associated ALI), only NAC has been used as a classic therapy for APAP-associated hepatotoxicity induced by NAPQI. In recent years, cimetidine has been used to reduce toxic metabolites by inhibiting cytochrome p450; thus, some researchers have suggested using cimetidine as a complementary treatment for AALI (Al-Mustafa et al., 1997). In addition, cimetidine is an available drug and its side effects could be found at very high doses (Woodhead et al., 2012). However, a double-blinded clinical trial involving 105 patients suspected of APAP toxicity who require medical treatment from Iran. Comparing the therapeutic efficacy of NAC or combination of NAC and cimetidine in patients with acute AALI, no significant improvement was found in hepatoprotective activities between intravenous administration of cimetidine (300 mg per 6 h) and the sole NAC treatment (Ebrahimi et al., 2015). However, the impact of cimetidine for prevention of ALI in individuals using APAP remains to be confirmed in the future.

APAP-Associated Idiosyncratic DILI

Both APAP-associated intrinsic and idiosyncratic DILI are defined by ALT elevation (≥5 × the upper limits of normal, resulting in difficulty in differentiating one from the other (Teschke and Zhu, 2018). Overdose of APAP (≥15 g) has been
reported to contribute to the classic intrinsic DILI, including ALF. However, low-dose use of APAP, including daily doses, may lead to idiosyncratic injury and liver adaptation (Yoon et al., 2016; Ramachandran and Jaeschke, 2018). In a Spanish study evaluating 32 prospectively gathered ALI cases, the APAP-associated Roussel Uclaf Causality Assessment Method (RUCAM) score was higher compared to that of other concomitant medications. The estimated incidence of AALI was 0.4 per million (99% confidence interval [CI], 0.2–0.8) in individuals >15 years of age and 10 per million (95% CI, 4.3–19.4) in APAP users (Sabate et al., 2011). In addition, APAP-associated idiosyncratic DILI was shown to have immunological manifestations, such as arthralgia, fever, eosinophilia, rash, and thrombocytopenia. Taken together, for rapid and precise detection and/or treatment of APAP-associated idiosyncratic DILI, it is necessary to assess the causality by the RUCAM score.

**APAP-Associated Liver Adaptation**

Liver adaptation to APAP may occur with therapeutic doses in some individuals. APAP overdose could cause ALF, but in several studies, repeated exposure to APAP led to autoprotective effects (Eakins et al., 2015). A randomized controlled trial identified that the incidence of ALT elevation (>3 × upper limits of normal) was 31% to 44% in treatment groups receiving APAP (Watkins et al., 2006). The median maximum ALT was 2.78 (95% CI, 1.47–4.09; P < 0.001) compared to placebo, suggesting history of APAP ingestion to be considered in differential diagnosis of ALT elevations regardless presence of serum APAP concentrations. Liver adaptation usually presents without clinical symptoms along with relatively low serum liver tests, including ALT that often remain at <5 × the upper limits of normal. Most of liver adaptations recover ALT levels that gradually drop to normal range, and no clinical decision is required. Therefore, even the serum APAP concentration is negative, a slight increase in liver tests without clinical manifestations or the history of APAP ingestion may refer to the liver adaptation.

**Advances in Herbal Therapy for ALI**

To date, a number of herbal extracts have been identified as effective for prevention of AALI with reasonable evidence in terms of effectiveness and safety (Table 1). In addition, there are also a number of therapeutic approaches using the natural product extracts after APAP administration with significant amelioration of the liver function and improved survival (Table 2).

**Adansonia digitata L.**

The methanol extract of *Adansonia digitata L.* (Malvaceae), which is a native tree in Central Africa and commonly known as baobab, fruit pulp (the pulp is dissolved in milk or water to be used as a drink or a sauce for food and is considered one of the popular ingredients in ice products) was also found to exert protective effects against ALI (Hanafy et al., 2016). The protection was mediated through attenuating lipid peroxidation by the scavenging activity of free radicals, as well as the antioxidant activities.

**Alnus japonica (Thunb.) Steud.**

Pretreatment with the stem bark of the Betulaceae plant *Alnus japonica* (Thunb.) Steud., a common folk medicine for cancer and hepatitis indigenous to Korea, revealed dose-dependent antioxidant effects in APAP-associated hepatotoxicity (Kim et al., 2004). The Alnus species are characterized by high amounts of the triterpenoids and diarylheptanoids compounds; thus, it is suggested that phenolic compounds may be associated with the antioxidant effects (Tadashi et al., 1990).
**TABLE 1** | Effects of bioactive natural product extract pretreatment in ALI.

| Herbal | Extract dose | APAP dose | Effect/mechanism | Ref. |
|--------|--------------|-----------|------------------|------|
| Acacia catechu (L.f.) Willd. | 400 mg/kg | 750 mg/kg | LPO accumulation | (Laikshmi et al., 2018) |
| Adansonia digitata L. | 200 mg/kg | 100 mg/kg | ALP, ALT, AST, MDA, SOD↓ | (El-Kott and Bin-Meferij, 2015) |
| Alnus japonica (Thurb.) Steud. | 200 μg/ml | 500 mg/kg | Antioxidant | (Kim et al., 2004) |
| Arctium lappa L. | 300 mg/kg | 800 mg/kg | ALP, ALT, AST, DNA fragmentation↓ | (El-Kott and Bin-Meferij, 2015) |
| Artemisia absinthium L. | 500 mg/kg | 640 mg/kg | MDME↓ | (Gilani and Janbaz, 1993) |
| Artemisia scoparia Waldst. & Kitam. | 150 mg/kg | 640 mg/kg | ALP, ALT↓ | (Gilani and Janbaz, 1995a) |
| Carnelia sinensis (L.) Kuntze (Green tea) | 1000 mg/kg | 200 mg/kg | ALT, AST, ALP, TB↓ | (Salminen et al., 2010; Wei et al., 2018) |
| Centaurea cyanus Rafn | 900 mg/kg | 750 mg/kg | ALT, AST, LDH↓ | (Mroueh et al., 2004) |
| Cuscuta campestris Lam. | 250 mg/kg | 835 mg/kg | ALP, ALT, AST, SOD, CAT, MDA↓ | (Yen et al., 2007) |
| Cuscuta chinensis | 250 mg/kg | 850 mg/kg | ALT, AST, SOD, CAT, MDA, GPx↓ | (Koca-Caliskan et al., 2018) |
| Cyperus scariosus | 500 mg/kg | 1 g/kg | ALP, ALT, AST↓ | (Gilani and Janbaz, 1995b) |
| Genista quadriflora Munby | 300 mg/kg | 1 g/kg | CYP2E1, GSTπ, TNF-α↓ | (Baaı̈ et al., 2016) |
| Glossocaridea bidens (Retz.) Veldkamp | 300 mg/kg | 500 mg/kg | ALT, AST↓ | (Tien et al., 2014) |
| Hydrastis canadensis L. | 1000 mg/kg | 400 mg/kg | ALT, AST, Cytochrome P450 2E1↓ | (Yamaura et al., 2011) |
| Musanga cecropioides R.Br. ex Tedlie | 500 mg/kg | 800 mg/kg | ALT, AST, OTC↓ | (Adeneye, 2009) |
| Paeonia × suffruticosa Lam. | 400 mg/kg | 400 mg/kg | ALT, GSH, Cytochrome P450 2E1, Hepatic DNA damage↓ | (Shon and Nam, 2004) |
| Premna tomentosa Willd. | 750 mg/kg | 640 mg/kg | Membrane-bound enzymes↓ | (Laikshimarayan and Muthana, 1953) |
| Prosopis farcta (Banks & Sol.) J.F.Macbr. | 75 mg/kg | 600 mg/kg | ALT, AST, TG, LDL, VLDL↓ | (Asadollahi et al., 2014) |
| Pterocarpus erinaceus Poiret. | 75 mg/kg | 2 g/kg | ALT, AST, MDA↓, GSH↑ | (Akinmoladun et al., 2015) |
| Sassa vetchii (Carrière) Rehder | 0.2 mL/day | 550 mg/kg | ALT, AST, JNK, RIP-1, CYP2E1↓ | (Zhang et al., 2014; Yoshioka et al., 2017) |
| Schisandra sphenanthera Rehder & E.H.Wilson | 700 mg/kg | 400 mg/kg | ALT, AST, MDA↓ | (Fan et al., 2014; Fan et al., 2015) |
| Teucrium polium L. | 250 mg/kg | 500 mg/kg | ALT, AST, ALP↓ | (Sakeran et al., 2014) |
| Trifolium alexandrinum L. | 300 mg/kg | 1 g/kg | CYP2E1, GSTπ, TNF-α↓ | (Forouzandeh et al., 2013) |
| Tournefortia sarmentosa Lam. | 500 mg/kg | 1000 mg/kg | MDA↓ | (Teng et al., 2012) |
| Zingiber officinalis Roscoe | 0.3 mL/kg | 600 mg/kg | ALP, ALT, AST, LDH, SDH↓ | (Yemitan and Izegbu, 2008) |
|     | 400 mg/kg | 3 g/kg | Antioxidant | (Aijboye et al., 2007) |

**TABLE 2** | Therapeutic effects of bioactive natural product after APAP overdose.

| Herbal | Extract dose | APAP dose | Effect | Ref. |
|--------|--------------|-----------|--------|------|
| Artemisia absinthium L. | 500 mg/kg | 640 mg/kg | MDME↓ | (Gilani and Janbaz, 1993) |
| Baccharis dracunculifolia DC. | 50 mg/kg | 600 mg/kg | ALT, AST, ALP | (Guimaraes et al., 2012) |
| Carnelia sinensis (L.) Kuntze (Green tea) | 1000 mg/kg | 150 mg/kg | ALP, ALT; GSH; AST, TB↓ | (Salminen et al., 2012; Wei et al., 2018) |
| Citrus × aurantium L. | 1000 mg/kg | 300 mg/kg | Survival rate | (Yamaura et al., 2012) |
| Hydrastis canadensis L. | 1000 mg/kg | 400 mg/kg | ALT, AST, Cytochrome P450 2E1↓ | (Yamaura et al., 2011) |
| Moringa oleifera Lam. | 400 mg/kg | 7 g/kg | GSH, SOD, CAT↓, Antioxidant | (Fakurazi et al., 2012; Sharifudin et al., 2013) |
| Phyllanthus urinaria L. | 200 mg/kg | 550 mg/kg | Cytochrome P450 2E1↓ | (Teng et al., 2012) |
| Punica granatum L. | 50 mg/kg | 750 mg/kg | ALT↓, Antioxidant | (Ahmad et al., 2016) |
| Tournefortia sarmentosa Lam. | 500 mg/kg | 1000 mg/ kg | ALP, ALT, TNF-α, IL-1β, IL-6, CAT, SOD, GPx↓ | (Teng et al., 2012) |
| Trifolium alexandrinum L. | 100 mg/kg | 100 mg/kg | ALP; ALT, GGTP, TB, MDA↓ | (Sakeran et al., 2014) |
| Vitex doniana Sweet | 400 mg/kg | 300 mg/kg | ALP, ALT, AST, GPx↓ | (Aijboye, 2015) |

**Arctium lappa L.**

A Saudi Arabian study have confirmed ameliorative effect of *Arctium lappa* L., which has been used as the tea, root extracts against ALI by confirmation on suppressed malondialdehyde content and mitigated most of the hepatic tissue damages caused by APAP overdose in rats, but some necrotic areas, as well as dilated and congested central vein, remained in Arctium lappa extract treatment group even 30 days after APAP treatment (El-Kott and Bin-Meferij, 2015). It is important to note that there was not full recovery from APAP-associated toxicity a month after the treatment.

**Artemisia scoparia Waldst. & Kitam. and Artemisia absinthium L.**

In 1993, hydromethanolic extract of *Artemisia scoparia* Waldst. & Kitam. (Compositae) was first reported to protect liver against...
APAP-induced hepatotoxicity (Gilani and Janbaz, 1993). Pretreatment of the extract (150 mg/kg) could significantly decrease the mortality by reducing serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels when applied APAP at a dose of 1 g/kg, which was a 100% lethal dose in the experiment. In addition, extract from Artemisia absinthium L. pretreated with aqueous-methanolic (Compositae) (500 mg/kg) also had the hepatoprotective effects by reducing ALT and AST levels, and inhibiting microsomal drug-metabolizing enzymes (Gilani and Janbaz, 1995a).

Baccharis dracunculifolia DC.
Glycolic extract of Baccharis dracunculifolia DC. that contains several chemical compounds, including caffeic acid, p-coumaric acid, cinnamic acid, aromadendrin, isosakuranetin, and artepillin C, was previously reported as the main source of green propolis with potent antioxidant activity that prevents against oxidative mitochondrial damage (Guimaraes et al., 2012). The extract of the leaves was tested in APAP-induced hepatotoxicity that revealed high total phenolic and flavonoid contents, which are hepatoprotective properties (Rezende et al., 2014).

Brassica juncea (L.) Czern. and Angelica keiskei (Miq.) Koidz.
Brassica juncea (L.) Czern. (Brassicaceae; Indian mustard) is considered to possess diverse pharmacological properties. The mustard seed extract was tested for APAP-induced toxicity in a hepatocellular carcinoma cell line (HepG2) and was found to have protective effects in both post and pretreatment models with a 20 mM APAP dose (Parikh et al., 2015). Phytochemical analysis showed the presence of vitamin, tannin, flavonoid, and phenolics, and the antioxidant activity revealed a linear correlation with the contents. However, the extent of ROS generation significantly differed that posttreatment inhibited the ROS generation by 58.4%, whereas pretreatment suppressed the generation of ROS by 90.5%. Further experiments confirmed the presence of vitamin E, quercetin, and ceterchin, which demonstrated hepatoprotective effect, and the ROS inhibition was confirmed to be associated with antioxidant activities, thus protecting against ALI. An ethanol extract of Angelica keiskei (Miq.) Koidz. was also tested in HepG2 and HepaRG cells by culturing with 30 mM APAP (Choi et al., 2017). The extract was found to downregulate apoptotic factors, such as caspase-3, -7, and -9, via intrinsic and extrinsic pathways to prevent ALI in APAP-induced hepatotoxicity.

Camellia sinensis (L.) Kuntze
Green tea comes from Camellia sinensis (L.) Kuntze. Salminen et al. (2012) tested the effect of green tea extract prior to and 6 h after APAP administration. Independently verified key components of the green tea extract batch GTE50-A0302031114 were polyphenols, catechins, gallates, caffeine, moisture, ash, heavy metals and residues, and these results suggest that green tea extract compounds may downregulate or suppress CYP1A2, 2E1, and 3A4 reduce APAP conversion to the reactive metabolite NAPQI. Interestingly, pretreatment of green tea extract revealed to provide protection against AALI by decreasing APAP covalent binding to protein, thus relatively reducing reactive metabolites for liver injury. However, green tea extract potentiated APAP-induced hepatotoxicity when applied after APAP treatment through causing glutathione depletion, indicating importance of the supplement interactions. Recently, Wei et al. (2018) found that the natural polyphenol chlorogenic acid is protective against APAP-induced hepatotoxicity through activation of Nrf2 antioxidant signalling pathway by blocking the binding of Nrf2 to Keap1. In addition, ERK1/2 plays a critical role in regulation of the polyphenol chlorogenic acid-derived Nrf2 transcriptional activation. These findings were further supported by a study from the United States that also confirmed increases in serum transaminases and histopathologic scores when administered the green tea extract after APAP (Lu et al., 2013).

Centaurium erythraea Rafn
The methanol extract of the leaves from Centaurium erythraea Rafn (Gentianaceae; 300 mg/kg per day for 6 days or 900 mg/kg for one day) was found the hepatoprotective effect against APAP-induced hepatotoxicity by reducing the serum concentration of ALT, AST, and lactate dehydrogenase (LDH) in patients (Mroueh et al., 2004).

Citrus × aurantium L.
The extract of a citrus fruit (natsumikan; Citrus × aurantium L.) that contains antioxidant nutrients, such as vitamin C and flavonoids, was found effective in improving survival of mice against acute ALI (Yamaura et al., 2012). Administration of 300 mg/kg of APAP led to 100% mortality within 6 h, but 1,000 mg/kg of natsumikan extract and silymarin prolonged survival rates to 33.3% and 50.0%, respectively.

Cuscuta chinensis Lam. and Cuscuta campestris Yunck.
The dual effects of ethanolic and aqueous extracts of the seeds of Cuscuta chinensis Lam. (Convolvulaceae), a traditional Chinese medicine used to nourish the liver and kidney, were found to notably reduce the concentration of ALT, AST, total bilirubin, and lactate dehydrogenase (LDH) in patients with APAP-induced hepatotoxicity (Yen et al., 2007). The ethanolic extract prevented the hepatotoxicity induced by APAP and had significant antioxidant activity, but the same dose of aqueous extract showed no hepatoprotective effect, and led to further deterioration of the liver, suggesting importance of the extract types. Moreover, the identified pharmacologically active constituents of the Cuscuta chinensis include polysaccharide, lignans, quinic acid, flavonol, and flavonoids (Du et al., 1998; Wang et al., 2000; Ye et al., 2002). Additionally, Yen et al. (2008) tested that the nanoparticle formulation of Cuscuta chinensis Lam. was superior to ethanolic extract/aqueous extract in terms of overcoming water-poorly-soluble and the decreasing the treatment dose. Furthermore, the aqueous and methanolic extracts of Cuscuta campestris Yunck. (125 and 250 mg/kg), a parasitic plant commonly known as dodder that is used as a folk medicine to treat liver-related diseases, were found to notably exert hepatoprotective and antioxidant effects (Koca-Caliskan et al., 2018).
Cyperus scariosus R.Br.

Further examination revealed that *Cyperus scariosus* R.Br. (Cyperaceae) extract (500 mg/kg) had a hepatoprotective effect confirmed by decreased the levels of ALT, AST, and alkaline phosphatase (ALP) in APAP overdose patients/mice (Gilani and Janbaz, 1995b).

Genista quadriflora Munby and Teucrium polium L.

Two of the endemic plants (*Genista quadriflora* Munby and *Teucrium polium* L.) in France that are frequently used for dietary and/or medical applications were tested and compared for its hepatoprotective effectiveness against APAP-induced hepatotoxicity in rats (Baali et al., 2016). Pretreatments of the rich-polyphenol fractions of them (300 mg/kg per day for 10 days) prior to oral administration of APAP (1 g/kg) exerted a hepatoprotective effect against ALI by improving transaminase leakage and enhancing antioxidant defense. In addition, suppressed miRNA expression of CYP2E1, GSTpi, and TNF-α along with enhanced mitochondrial bioenergetics were suggested to be responsible for the protective effect. It was further suggested that predominant flavonoids and phenolic acids in the extracts may have contributed to the high total polyphenol content.

Glossocardia bidens (Retz.) Veldkamp

In BALB/c mice, hot water extracts of *Glossocardia bidens* (Retz.) Veldkamp was found to contain high phenolics (chlorogenic acid and luteolin-7-glucoside). The extracts were effective at protecting against ALI by increasing glutathione levels, reducing the ratio of glutathione to oxidized glutathione in the liver, and inhibiting peroxidation to exert antioxidant ability (Tien et al., 2014). In addition, the antioxidant capacity of *Glossocardia bidens* (Retz.) Veldkamp was dependent on the type of the solvents, including hot water, 50% ethanol, and 95% ethanol. It is crucial to note that the capacity was most excellent when applied hot water.

Hovenia Dulcis Thunb.

In China, although *Hovenia Dulcis* Thunb is frequently used to protect the liver against alcoholic injury, its impact against APAP-induced hepatotoxicity remained unclear. Dong et al. (2011) have con

Hydrastis canadensis L.

Goldenseal (*Hydrastis canadensis* L.) was further confirmed to be protective against AALI by inhibiting CYP2E1 in rats (Yamaura et al., 2011). Moreover, goldenseal can also inhibit the cytochrome P450 isoforms, including CYP1A2, CYP2D6, CYP2E1, and CYP3A, and the IC₅₀ values were 15.7, 7.4, 4.3, and 52.1 μg/ml in rats, respectively.

Moringa oleifera Lam.

Fakurazi et al. (2012) found that the administration (1 h after APAP) of extract from *Moringa oleifera* Lam. (Moringaceae), an antioxidant with abundant essential minerals, was significantly effective in reducing malondialdehyde and 4-hydroxynonenal protein adduct levels. In addition, the Folin-Ciocalteu assay of the total phenolic compounds revealed that the ethanolic extract of *Moringa oleifera* has the highest total phenolic content (24.21 ± 1.55 mg gallic acid equivalent/100 g dw followed by leaves, pods, seeds, and stem. Further research confirmed that administration of the extract alleviated the severity of liver injury (Sharifudin et al., 2013).

Musanga cecropioides R.Br. ex Tedlie and Vitex doniana Sweet

Pretreatment with aqueous extract of the stem bark *Musanga cecropioides* R.Br. ex Tedlie (125–500 mg/kg), which is used as a natural antidote for gastric poisoning in Southwest Nigeria, significantly ameliorated acute elevation of the liver enzymes and hepatotoxicity-associated histopathological lesions within the liver by activating natural antioxidants (flavonoid and alkaloid) (Adeneye, 2009). The extract of another local Nigerian remedy (*Vitex doniana* Sweet) for the treatment of liver-related diseases was also assessed in APAP-induced hepatotoxicity (Ajiboye, 2015). GC-MS profiling on methanolic extract of *Vitex doniana* fruits indicated 13 different phytoconstituents with β-sitosterol, which was found to have antioxidant and antiradical activities, as the most abundant compound, followed by platycodin D, apigenin, saikosaponinn, and chrysos. The extract significantly attenuated serum liver enzymes and ameliorated the reduction in superoxide dismutase, catalase, glutathione peroxidase and reductase, and 6-phosphate dehydrogenase activities. Furthermore, the increased conjugated dienes, lipid hydroperoxides, and fragmented DNA levels were significantly decreased when administered methanolic extract of *Vitex doniana* Sweet.

Paeonia × suffruticosa Andrews

In the early 21st century, Shon et al. (2004) explored the impact of cortex of *Paeonia × suffruticosa* Andrews and its underlying mechanisms. Administration of cortex of *Paeonia × suffruticosa* Andrews could prevent liver injury by decreasing ALT, protecting against hepatic glutathione depletion, attenuating cytochrome P450 2E1 activity, and preventing hepatic DNA damage in vivo.

Passiflora subpeltata Ortega

According to a study from Brazil, luteolin and quercetin 3-β-d-glucoside were newly detected as compounds in *Passiflora subpeltata* Ortega leaves, and an acetone extract of this plant was found to elevate the serum white blood cell, red blood cell, and hemoglobin counts, and retain the serum biochemical and antioxidant levels to normal range, providing protection against ALI (Shanmugam et al., 2016).
**Phyllanthus urinaria L.**

Oral administration of *Phyllanthus urinaria* L. extract following intraperitoneal administration with a lethal dose of APAP was found to be protective against APAP-induced necrosis by downregulating the cytochrome P450 CYP2E1 protein levels *in vitro* (Hau et al., 2009). In addition, a therapeutic dose of *Phyllanthus urinaria* showed no toxicological phenomena in mice.

**Premna tomentosa Willd.**

Pretreatment with an extract from Indian traditional medicine *Premna tomentosa* Willd. (Lamiaceae) (750 mg/kg for 15 days) before APAP administration (640 mg/kg). It was found that the Indian traditional medicine could prevent the liver injury-induced membrane damage, suggesting the presence of antioxidant compound limonene (Devi et al., 2004). In addition, previous preliminary phytochemical screening confirmed the presence of limonene (57.8%) along with other phytoconstituents, including beta-caryophyllene (17.2%), cadalene type sesquiterpene (7.8%), ses quiterpene tertiary alcohol (5.6%), and aditerpene (5.5%) (Lakshimaran and Muthana, 1953).

**Prosopis farcta (Banks & Sol.) J.F.Macbr.**

Extract of *Prosopis farcta* (Banks & Sol.) J.F.Macbr. beans were previously found to contain a number of antioxidant phenolic compounds, such as vicenin-2, vitexin, glucose, and luteolin. In Wister albino rats weighing approximately 200 g, 600 mg/kg of APAP administration significantly increased ALT, AST, cholesterol, and low-density lipoprotein, which were attenuated to near normal ranges when administrated 50 and 75 mg/kg of *Prosopis farcta* (Banks & Sol.) J.F.Macbr. beans. Administration of bean extract prior to APAP resulted in hepatoprotective activity against ALI despite relatively low doses (Asadollahi et al., 2014).

**Pterocarpus erinaceus** Poir., Bilberries, and Blackcurrants

Akinmoladun and colleagues explored the hepatoprotective effects of pretreatments of the ethanol stem bark extract and the constituent flavonoid (homopterocarpin) against APAP (2 g/kg). It was found that these substances ameliorated APAP-associated biochemical alterations. Furthermore, higher antioxidant potentials potential was found in homopterocarpin compared to the ethanol stem bark extract, suggesting the importance of the extract types in preventive efficacy against ALI (Akinmoladun et al., 2015). In addition, an anthocyanin-risk extract from bilberries and black currants was also found to be protective against acute ALI in rats (Cristani et al., 2016).

**Punica granatum L.**

Surprisingly, 14 days of treatment with *Punica granatum* L. methanolic extract was reported to have very strong effects in ameliorating liver functions after APAP treatment (750 mg/kg) potentially by antioxidant properties that the mean liver ALT and AST levels were even lower in the pomegranate peel posttreatment group after APAP treatment (ALT, 49.6 ± 12.1; AST, 96.1 ± 18.0) compared to the normal saline group without APAP treatment (ALT, 51.5 ± 15.4; AST, 97.9 ± 19.5) (Ahmad et al., 2016).

**Sasa veitchii** (Carrière) Rehder and *Acacia catechu* (L.f.) Willd.

In accordance with other extracts from natural products, 7 days of a *Sasa veitchii* (Carrière) Rehder leaf extract (0.2 ml per day) pretreatment significantly decreased hepatic injury markers, including ALT and AST, oxidative stresses, including malondialdehyde and glutathione, histologic damages, inflammatory cytokines, activation of JNK, receptor-interacting protein-1, which has emerged as a key modulator of necrotic cell death, and CYP2E1, whereas the total antioxidant capacity within the liver was increased in an acute APAP mice model (550 mg/kg) (Zhang et al., 2014; Yoshioka et al., 2017). More recently, the seed and bark extracts (400 mg/kg) of *Acacia catechu* (L.f.) Willd. were also found to modulate oxidative stress, antioxidative activities, and liver function to protect against APAP-induced hepatotoxicity in rats with higher potentials in the seed extract for protection of the liver (Lakshmi et al., 2018).

**Schisandra sphenanthera** Rehder & E.H.Wilson and *Schisandra chinensis* (Turcz.) Baill.

In many regions, *Schisandra sphenanthera* Rehder & E.H.Wilson is widely used to support liver function and is applied in the form of Wuzhi tablet, which is composed of ethanol extracts. Administration of Wuzhi tablet 3 days prior to APAP treatment could significantly alleviate hepatotoxicity in a dose-dependent manner along with reduction in the activation of JNK (Fan et al., 2014). In addition, potent inhibition of the activities of CYP2E1, CYP3A11, CYP1A2, and KEAP1, and the formation of the oxidized APAP metabolite NAPQI-reduced glutathione, whereas Nrf2 expression was increased. Moreover, pretreatment with Wuzhi tablet suppressed the p53/p21 signalling pathway, which induces cell proliferation proteins that enhance proliferation of hepatocytes. More recently, they compared therapeutic efficacy of Wuzhi tablet to N-acetylcysteine, which is the main antidote for APAP toxicity (Fan et al., 2015). When administered Wuzhi tablet 4 h after APAP treatment, it revealed much better therapeutic impact compared to N-acetylcysteine, which were confirmed by morphological, histological, and biochemical evaluations. In addition, Wuzhi tablet additionally stimulated liver regeneration after injury, which were verified by increased expressions of cyclin D1, proliferating cell nuclear antigen, and liver regeneration augmenters. Recently, the extracts of *Schisandra chinensis* (Turcz.) Baill. stems revealed to exert significant amelioration in APAP-induced apoptosis, inflammation, and oxidative stress through regulation of mitogen-activated protein kinase and caspase-3 signaling pathway (Li et al., 2018).
(Yen et al., 2008). Pretreatment with the extract of another Chinese herbal medicine, [Tournefortia sarmentosa Lam. (Boraginaceae)] which is commonly used as an anti-inflammatory or detoxificant agent, showed significantly reduced serum concentrations of ALT, AST, ALP, and inflammatory markers (Teng et al., 2012).

_Trfioliu alexandrinum L. and Teucrium polium L._

According to Sakeran et al. (2014) compared the APAP group to the APAP plus _Trfiliolium alexandrinum_ L. root extract group, the extract improved ALI in terms of histopathology and DNA fragmentation. Pretreatment of _Teucrium polium_ L. (Labiatae) extract was also found to be protective against ALI at doses of 250 and 500 mg/kg as confirmed by histological examinations (Forouzandeh et al., 2013).

_Zingiber officinale Roscoee_

Ethanol extract of the rhizome of _Zingiber officinale_ Roscoee was effective in ameliorating liver function as confirmed by attenuated serum ALT, AST, ALP, LDH, and succinate dehydrogenase (Yemitan and Izebugu, 2006). _Zingiber officinale_ Roscoee also prevented APAP-induced acute hepatotoxicity by preventing the decline of liver antioxidant status or on account of the radical scavenging capacity (Ajith et al., 2007). Because of the crucial involvement of oxidative damage in AALI, antioxidant properties were further tested in AALI.

**FUTURE PERSPECTIVES AND CONCLUSIONS**

Since the early 1990s, numerous extracts from various natural products have been identified as hepatoprotective at different doses against APAP-induced toxicity by ameliorating oxidative stress and liver enzymes. Despite a large amount of effort and many publications, most studies have testified effects of the extract pretreatment prior to acute APAP administration on serologic, histologic, and morphologic liver-related outcomes in vivo, but few studies have explored these effects in hepatic cell lines by culturing with the natural products and administering APAP. In addition, some of the products contained compounds even more effective than the antidote (NAC) when treated after APAP administration. Few studies have compared these highly effective products, and it is still a challenge to determine the greatest potential products. Therefore, it seems to us that only the number of hepatoprotective products has increased without clinical relativity. Recently, gut microbiota was identified to play a key role in the diurnal variation of APAP-induced hepatotoxicity (Gong et al., 2018). Accumulating evidence implicates herbas could treat disease by regulating the gut microbiota (Tong et al., 2018; Anlu et al., 2019; Feng et al., 2019). More studies are needed to verify whether the hepatoprotective effect of natural products through this novel mechanism. In addition, further identifications of the following factors may support prevention and treatment of ALI: specific inhibitors of CYPs such as CYP2E1; induction of detoxifying enzymes (UGT, SULT, etc.) that participate in APAP metabolism (Wang et al., 2015; Cao et al., 2017); treatments to increase or supplement of GSH or NAC to inactivate the reactive metabolite NAPQI rapidly; factors associated with reducing formations of oxidative stress and oxygen free radicals, and protective and preventive factors against mitochondrial damage since mitochondrial dysfunction and damage plays pivotal role in APAP-associated ALI (Shan et al., 2018). As is known in China and other Asian countries, herbal medicines have been widely used in clinical settings. In order to ensure the efficacy and repeatability in herbal medicines, the Chinese government has required all manufacturers to formulate strict quality standards for each herb product. Currently, the majority of herbal medicines used in the clinical settings are produced by several large pharmaceutical companies rather than traditional decocting modes. In fact, part of the herbal medicines used for alleviating ALI are granules of a single herb or several herbs, their major constituents have been reported previously. However, herbal therapy for APAP-induced liver injury remains limited in terms of clinical application due to prospective validation by clinical trials. In addition, individual compounds of the herbal extracts are barely studied even in experimental animal models.

The potential hepatotoxicity of herbal products has also been recognized in recent years (Stickel and Shouval, 2015). Many herbal products have been reported by numerous studies to cause liver injury. The clinical symptoms ranging from acute chronic hepatitis to ALF (Frenzel and Teschke, 2016; Zhu et al., 2019). Although oxidative stress and necrosis were reported to be related to herbal products toxicities, the underlying mechanism is largely unknown (Stickel and Shouval, 2015). More studies are needed to explore the mechanism of natural products side effect. Due to their multicomponent nature and multitargeted and synergistic effects, it is extremely challenging to study the specific molecular mechanism of herbal medicine to alleviate APAP-induced liver injury. In future, the researchers may use the information listed in this review as a clue to deeply understand the bioactive compounds in these herbal medicines for alleviating APAP-induced hepatotoxicity, and their mechanisms of action. Considering the preventive, protective, and therapeutic effectiveness of the herbal therapies, evaluation of efficacy and safety in clinical trials may also be promising in the future after further confirming effects of each extract type, interactions between the supplements, and synergism between products.

**AUTHOR CONTRIBUTIONS**

LC, DX, and JZ: design of the study and writing of the manuscript. GG, XK, and YZ: revision of the manuscript and final approval.

**FUNDING**

This work was supported by Shanghai Pudong Commission of Health and Family Planning (PWRd2016-12) to YZ, Talents
REFERENCES

Adeneye, A. A. (2009). Protective activity of the stem bark aqueous extract of Musanga cecropioides in carbon tetrachloride- and acetaminophen-induced acute hepatotoxicity in rats. Afr. J. Tradit. Complement. Altern. Med. 6 (2), 131–138. doi: 10.4314/african.v6i2.57084

Ahmad, N., Tahir, M., and Lone, K. P. (2016). Amelioration of acetaminophen induced hepatotoxicity by methanolic extract of pomegranate peels in rats. J. Pak. Med. Assoc. 66 (7), 859–863.

Ajiboye, T. O. (2015). Standardized extract of Vitex doniana Sweet stalls protein oxidation, lipid peroxidation and DNA fragmentation in acetaminophen-induced hepatotoxicity. J. Ethnopharmacol. 164, 273–282. doi: 10.1016/j.jep.2015.01.026

Ajith, T. A., Hema, U., and Aswathy, M. S. (2007). Zingerib officinale Roscoe prevents acetaminophen-induced acute hepatoxicity by enhancing hepatic antioxidant status. Food Chem. Toxicol. 45 (11), 2267–2272. doi: 10.1016/j.fct.2007.06.001

Akimoladun, A. C., Olailey, M. T., Komolafe, K., Adeyuti, A. O., and Akindahunsi, A. A. (2015). Effect of homopterocarpin, an isoflavonoid from Pterocarpus erinaceus, on indices of liver injury and oxidative stress in acetaminophen-provoked hepatotoxicity. J. Basic Clin. Physiol. Pharmacol. 26 (6), 555–562. doi: 10.1515/jbcpp-2014-0095

Al-Mustafa, Z. H., Al-Ali, A. K., Qaw, F. S., and Abdul-Cader, Z. (1997). Antituberculosis Drugs on CYP3A4, CYP2C9 and UDP-glucuronosyltransferase Enzymes. J. Pak. Med. Assoc. 104, 228–234.

Aminoshariae, A., and Khan, A. (2015). Acetaminophen: old drug, new issues. J. Endod. 41 (5), 588–593. doi: 10.1016/j.iendoj.2015.01.024

Anlu, W., Dongcheng, C., He, Z., Qiuyi, L., Yan, Z., Yu, Q., et al. (2019). Using Teucrium polium geyrii Maire in Acetaminophen-Induced Hepatotoxicity in Wister Rats. Int. J. Prev. Med. 10 (1), 66. doi: 10.4162/ijpam.2017.11.2.97

Craig, D. G., Lee, A., Hayes, P. C., and Simpson, K. J. (2010). Review article: the current management of acute liver failure. Aliment. Pharmacol. Ther. 31 (3), 345–358. doi: 10.1111/j.1365-2036.2009.04175.x

Cristani, M., Speciale, A., Mannari, F., Arcoraci, T., Ferrari, D., Fratantonio, D., et al. (2016). Protective activity of an anthocyanin-rich extract from bilberries and blackcurrants on acute acetaminophen-induced hepatotoxicity in rats. Nat. Prod. Res. 30 (24), 2845–2849. doi: 10.1080/14786419.2016.1160235

Dahlin, D. C., Miwa, G. T., Lu, A. Y., and Nelson, S. D. (1984). N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc. Natl. Acad. Sci. U. S. A. 81 (5), 1327–1331. doi: 10.1073/pnas.81.5.1327

Davvern, T. J.2nd, James, L. P., Hison, J. A., Polson, J., Larson, A. M., Fontana, R. J., et al. (2006). Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology 130 (3), 687–694. doi: 10.1053/j.gastro.2006.01.033

Devi, K. P., Sreepriya, M., Balakrishna, K., and Devaki, T. (2004). Protective effect of Prenna tomentosa (L. Verbenaceae) extract on membrane-bound phosphatases and inorganic cations transport in acetaminophen-induced hepatotoxicity rats. J. Ethnopharmacol. 93 (2-3), 371–375. doi: 10.1016/j.jep.2004.04.010

Dong, H., Haining, R. L., Thummel, K. E., Rettie, A. E., and Nelson, S. D. (2000). Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab. Dispos. 28 (12), 1397–1400. doi: 10.1093/dmd/28.12.1397-1400

Dong, S., Ji, Z., Zhang, B., Hu, L., Cui, X., and Wang, H. (2018). Protective effects and possible molecular mechanism of Hovenia dulcis Thunb. extract on acetaminophen-induced hepatotoxicity. Pharmazie 73 (11), 666–670. doi: 10.1691/ph.2018.8650

Du, X. M., Kohinata, K., Kawasaki, T., Gao, Y. T., and Miyahara, K. (1998). Components of the ether-insoluble resin glycoside-like fraction from Cuscuta chinensis. Phytochemistry 48 (5), 843–850. doi: 10.1016/s0031-9422(97)00990-4

Du, K., Ramachandran, A., and Jaeschke, H. (2016). Oxidative stress during acetaminophen hepatotoxicity: Sources, pathophysiological role and therapeutic potential. Redox Biol. 10, 148–156. doi: 10.1016/j.redox.2016.10.001

Du, K., Ramachandran, A., Weemhoff, J. L., Chavan, H. Xie, Y., Krishnamurthy, P., et al. (2016). Editor’s Highlight: Metformin Protects Against Acetaminophen Hepatotoxicity by Attenuation of Mitochondrial Oxidant Stress and Dysfunction. Toxicol. Sci. 154 (2), 214–226. doi: 10.1095/toxsci.k118

Eakins, R., Walsh, J., Randle, L., Jenkins, R. E., Schuppe-Koistinen, I., Rowe, C., et al. (2015). Adaptation to acetaminophen exposure elicits major changes in the expression and distribution of the hepatic proteome. Toxicol. Sci. 154 (2), 222–230. doi: 10.1095/toxsci.k118

Ebrahimi, M., Mousavi, S. R., Toussi, A. G., Reihani, H., and Bagherian, F. (2015). Use of Arctium lappa Extract Against Acetaminophen-Induced Hepatotoxicity in Rats. Curr. Ther. Res. Clin. Exp. 77, 73–78. doi: 10.1016/j.theres.2015.05.001

Frontiers in Pharmacology | www.frontiersin.org 10 March 2020 | Volume 11 | Article 313

Chang et al. Herbal Therapy for Acetaminophen-Associated Liver Injury

Training Program of the Seventh People’s Hospital, Shanghai University of Traditional Chinese Medicine (XX2020-19) to LC; National Natural Science Foundation of China (81504949 and 81873590) to JZ, National Natural Science Foundation of China (81922070), Shanghai City Youth Science and Technology Star Project (19QA1405500) to JZ; Shanghai City Youth Science and Technology Yangfan Project (19YF1428200) to DX; National Natural Science Foundation of China (81670562) to XK.
Ye, M., Li, Y., Yan, Y., Liu, H., and Ji, X. (2002). Determination of flavonoids in Semen Cuscutae by RP-HPLC. *J. Pharm. BioMed. Anal.* 28 (3-4), 621–628. doi: 10.1016/s0731-7083(01)00672-0

Yemitan, O. K., and Izegbu, M. C. (2006). Protective effects of Zingiber officinale (Zingiberaceae) against carbon tetrachloride and acetaminophen-induced hepatotoxicity in rats. *Phytother. Res.* 20 (11), 997–1002. doi: 10.1002/ptr.1957

Yen, F. L., Wu, T. H., Lin, L. T., and Lin, C. C. (2007). Hepatoprotective and antioxidant effects of Cuscuta chinensis against acetaminophen-induced hepatotoxicity in rats. *J. Ethnopharmacol.* 111 (1), 123–128. doi: 10.1016/j.jep.2006.11.003

Yen, F. L., Wu, T. H., Lin, L. T., Cham, T. M., and Lin, C. C. (2008). Nanoparticles formulation of Cuscuta chinensis prevents acetaminophen-induced hepatotoxicity in rats. *Food Chem. Toxicol.* 46 (5), 1771–1777. doi: 10.1016/j.fct.2008.01.021

Yoon, E., Babar, A., Choudhary, M., Kutner, M., and Pyrsopoulos, N. (2016). Acetaminophen-Induced Hepatotoxicity: a Comprehensive Update. *J. Clin. Trans. Hepatol.* 4 (2), 131–142. doi: 10.14218/jcht.2015.00052

Yoshioka, H., Usuda, H., Fujii, H., and Nonogaki, T. (2017). Sasa veitchii extracts suppress acetaminophen-induced hepatotoxicity in mice. *Environ. Health Prev. Med.* 22 (1), 54. doi: 10.1186/s12199-017-0662-3

Zand, R., Nelson, S. D., Slattery, J. T., Thummel, K. E., Kalhorn, T. F., Adams, S. P., et al. (1993). Inhibition and induction of cytochrome P450E1-catalyzed oxidation by isoniazid in humans. *Clin. Pharmacol. Ther.* 54 (2), 142–149. doi: 10.1038/clpt.1993.125

Zhang, Y. F., He, W., Zhang, C., Liu, X. J., Lu, Y., Wang, H., et al. (2014). Role of receptor interacting protein (RIP)1 on apoptosis-inducing factor-mediated necroptosis during acetaminophen-evoked acute liver failure in mice. *Toxicol. Lett.* 225 (3), 445–453. doi: 10.1016/j.toxlet.2014.01.005

Zhu, J., Chen, M., and Borlak, J. (2019). The landscape of hepatobiliary adverse reactions across 53 herbal and dietary supplements reveals immune-mediated injury as a common cause of hepatitis. *Arch. Toxicol.* 94 (1), 273–293. doi: 10.1007/s00204-019-02621-4

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.